Cancer Biology

  4. Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

    1. Veera K. Ojala
    2. Sini Ahonen
    3. Sara Peltola
    4. Aura Tuohisto‐Kokko
    5. Olaya Esparta
    6. Peppi Suominen
    7. Anne Jokilammi
    8. Iman Farahani
    9. Deepankar Chakroborty
    10. Nikol Dibus
    11. Steffen Boettcher
    12. Tomi T. Airenne
    13. Mark S. Johnson
    14. Lisa D. Eli
    15. Klaus Elenius
    16. Kari J. Kurppa

    Reviewed by Review Commons

    4 evaluationsAppears in 1 listLatest version Latest activity

  5. Tumoral CD24 tunes platelets binding and pro-metastatic functions

    1. Vincent Mittelheisser
    2. Cristina Liboni
    3. Clarisse Mouriaux
    4. Silvia Maria Grazia Trivigno
    5. Louis Bochler
    6. Maria Garcia-Leon
    7. Annabel Larnicol
    8. Laetitia Paulen
    9. Tristan Stemmelen
    10. Pierre Henri Mangin
    11. Olivier Lefebvre
    12. Jacky G. GOETZ

    Reviewed by preLights

    1 evaluationAppears in 1 listLatest version Latest activity

  8. Reduced mitochondrial transcription sensitizes acute myeloid leukemia cells to BCL-2 inhibition

    1. Laleh S Arabanian
    2. Jenni Adamsson
    3. Anke Unger
    4. Raffaella Di Lucrezia
    5. Tim Bergbrede
    6. Arghavan Ashouri
    7. Erik Larsson
    8. Peter Nussbaumer
    9. Bert M Klebl
    10. Lars Palmqvist
    11. Claes M Gustafsson

    • Curated by eLife

      eLife Assessment

      This solid study assesses a mitochondrial polymerase inhibitor in combination with the BCL-2 inhibitor venetoclax, with the aim to increase the elimination of acute myeloid leukemia. It provides valuable findings of combinatorial efficacy using preclinical models in vitro and in vivo, confirming the overall importance of targeting oxidative phosphorylation to overcome venetoclax resistance in acute myeloid leukemia, and could be strengthened through mechanistic studies demonstrating on target effects and pharmacodynamic efficacy in vivo. The study is of interest to hematologists because it addresses a key biomedical issue in acute myeloid leukemia (venetoclax resistance) and provides data regarding the safety and activity of a novel inhibitor of the mitochondrial polymerase in combination with venetoclax.

    Reviewed by eLife

    7 evaluationsAppears in 1 listLatest version Latest activity

  10. Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

    1. Aamena Y. Patel
    2. Peyman Zarrineh
    3. Nathnael T. Tuffa
    4. Jigar H. Sheth
    5. Sumitra Mohan
    6. Mudassar Iqbal
    7. Sankari Nagarajan

    Reviewed by Review Commons

    4 evaluationsAppears in 1 listLatest version Latest activity
Previous Page 8 of 44 Next